Table 5.
PFS according to lines of treatment
| Survivors < 4 years (n = 188) | Long-term survivors (≥ 4 years) (n = 60) | p value | ||||
|---|---|---|---|---|---|---|
| n | PFS (months) (IQR) | n | PFS (months) (IQR) | |||
| 1st-line overall | Median (interval) (months) | 188 | 10.8 (0.7–46.6) | 60 | 15.7 (3.5–69) | 0.0001 |
| Type of treatment | Chemotherapy plus bevacizumab | 71 | 12 (1–46.6) | 13 | 25.9 (11.6–69) | |
| Chemotherapy plus anti-EGFR | 7 | 16.1 (6.5–32) | 1 | 5.1 | ||
| Chemotherapy alone | 110 | 10.1 (0.7–39.1) | 46 | 13.1 (3.5–60.8) | ||
| 2nd-line overall | Median (interval) (months) | 154 | 4.4 (0.2–21.9) | 51 | 9.8 (2.0–47.8) | < 0.001 |
| Type of treatment | Chemotherapy plus bevacizumab | 25 | 5.7 (1.3–19.4) | 8 | 9.45 (2.1–24.3) | |
| Chemotherapy plus anti-EGFR | 28 | 3.05 (0.2–14.1) | 5 | 10.3 (2.5–24.7) | ||
| Chemotherapy alone | 101 | 4.3 (0.2–21.9) | 38 | 9.65 (2–47.8) | ||
| 3rd-line overall | Median (interval) (months) | 103 | 3.2 (0.6–20.2) | 43 | 7.6 (0.2–33) | < 0.001 |
| Type of treatment | Chemotherapy plus bevacizumab | 1 | 4.65 (2.6–6.7) | 3 | 8 (7.3–16.2) | |
| Chemotherapy plus anti-EGFR | 33 | 3.45 (0.6–9.9) | 17 | 8.1 (1.9–33) | ||
| Chemotherapy alone | 69 | 3.1 (0.4–20.2) | 23 | 7.1 (0.2–28) | ||
| 4th-line overall | Median (interval) (months) | 51 | 2.6 (0.6–8.8) | 28 | 7.7 (2.2–17.9) | < 0.001 |
| Type of treatment | Chemotherapy plus bevacizumab | 0 | – | 1 | 12.1 | |
| Chemotherapy plus anti-EGFR | 5 | 4.1 (2.6–8.8) | 6 | 15.5 (8.2–17.9) | ||
| Chemotherapy alone | 46 | 2.6 (0.6–7) | 21 | 6.35 (2.2–17.1) | ||